Patients meeting all four conditions at week 16 achieved this end point.

Results: The primary end point of the phase I trial is safety.

The right to vote was a beginning rather than an end point.

Specific growth delay was used as the end point for tumor response.

The primary efficacy end point was the absolute change in body weight.

Primary end point was all-cause mortality within 90 days after index BSI.

Conclusion: Our study did not meet the primary end point of OS.

The primary end point was the 30-day incidence of major adverse events.

The primary end point was survival free from any appropriate ICD therapy.

The primary safety end point was the development of clinically significant arrhythmia.

The field effect might provide an end point in chemopreventive intervention trials.

The end point of the follow-up was an incident case of stroke.

The primary end point was safety, including the incidence of dose-limiting toxicities.

I was willing to drop my question about having an end point.

We analyzed the impact of both conditions on the primary end point.

Two hundred four patients were available for evaluation at the end point.